Application of corynebacterium diphtheroid as immune adjuvant in poultry oil emulsion inactivated vaccine

Abstract

The invention discloses application of corynebacterium diphtheroid as an immune adjuvant in a poultry oil emulsion inactivated vaccine. The corynebacterium diphtheroid refers to the corynebacterium similar to corynebacterium diphtheriae in respect of morphological and biological characteristics, namely the low-pathogenic or non-pathogenic corynebacterium except the high-pathogenic corynebacteriumdiphtheriae. The corynebacterium diphtheroid active adjuvant disclosed by the invention has high immunity stimulation activity and can be used for non-specifically stimulating the immune functions ofT and B lymphocytes so as to promote secretion of a plurality of cytokines; by adding the immune adjuvant into the poultry oil emulsion inactivated vaccine, the vaccine induced generation of animal antibody can be obviously promoted.

Description

technical field [0001] The invention relates to the technical field of microbes, in particular to the application of a coryneform bacillus diphtheriae as an immune adjuvant in an inactivated poultry oil emulsion vaccine. Background technique [0002] In recent years, especially after the outbreak of avian influenza, poultry oil emulsion inactivated vaccine has become the most important type of poultry vaccine. However, poultry oil emulsion inactivated vaccines are easily affected by the quality of inactivated antigens, especially high-quality vaccines are generally achieved through high-power concentrated antigen technology, and high-quality poultry oil emulsion inactivated vaccines have high production costs and limited production capacity , cannot effectively meet the market demand. Therefore, research and development of safe, efficient and economical immune adjuvants for poultry oil emulsion inactivated vaccines has become a research focus. [0003] Immune adjuvants, al...

AI Technical Summary

Problems solved by technology

At present, the following problems generally exist in immune adjuvants: (1) inactivated Mycobacterium tuberculosis adjuvants, due to the high virulence of natural Mycobacterium tuberculosis, are pathogenic to humans and animals, so at present, attenuated mycobacterium tuberculosis is used BCG-based adjuvant preparation, but there are still high requirements for follow-up processing, which may easily lead to incomplete inactivation and cause high animal health hazards when used as an adjuvant. In addition, it may cause serious animal adverse reactions or local granulomatous lesions. In addition, the bacterial fermentation conditions are strict, the fermentation period is long, the growth is slow, and the nutritional requirements are high, so it is strictly prohibited to be used in commercial vaccines

(2) Thymosin has been used in the treatment of human tumors, but it is expensive and cannot be used in animal vaccines

(3) double-stranded polynucleotide (polyinosin) has become a conventional antitumor drug, but in view of its short half-life and transient reaction in vivo, its effectiveness as an immune adjuvant for poultry oil emulsion inactivated vaccines is still limited. clear

(4) Aluminum hydroxide aluminum gel adjuvant is currently a commonly used adjuvant for animal vaccines. It mainly exerts the adjuvant effect by making the antigen-adjuvant complex form a sustained release effect at the injection site and stimulates the immune response to a certain extent. Bacterial vaccines are significantly more effective than viral vaccines, and adjuvant stimulation is limited

[0004] To sum up, there is currently a lack of truly efficient and economical adjuvants for animal vaccines on the market. Therefore, the use of new immune adjuvants to improve the immune effect of animals has become an important problem to be solved urgently in the livestock and poultry breeding industry.

Images